Medical network - March 23, 2000-2009, China has adjusted version released three drugs directory, were 2000, 2004 and 2004. Along with our country economic development, extended life expectancy, changes in disease, the medical technology development, medicine for patients with drug expenses burden change and other factors change, the medical insurance directory updated once arguably need 5 years, but has not released 2014 medicare directory.
And other major diseases in our country in recent years, tumor growth, some curative effect is remarkable for certain drugs can't included in the list has the necessity of the medical insurance directory update more and highlight the 2009 version, on February 23, 2017 the new medical insurance directory finally born, the version of the directory to reflect the three "feeling".
T-shirts tumor patients mood
According to the lancet study recently published by the Chinese cancer health care costs, China each newly diagnosed cancer patients from 10 months after diagnosis out-of-pocket medical expenses as much as $4947, accounting for 57.5% of household income. Many patients just out of poverty or rich Chinese due to disease or expensive medical costs, including expensive cancer accounts for the bulk drug treatment.
Even though some multinational pharmaceutical companies product can charity give medicine, but after all the sun can't shine on each patient. Such as its ehrs - 2 positive breast cancer patient with herceptin, not charity subsidies, patients' out-of-pocket payment part, at least for more than 10 ten thousand yuan, most of the Chinese people are not.
The medical insurance directory update t-shirts, four new targeted drug is very expensive, respectively is ek, for the treatment of sand for, and imatinib. These drugs mainly treatment of lung cancer, leukemia, etc. Other new pemetrexed, his west marina, blister beetle acid sodium vitamin B6, IDA than star is tumor such as lung cancer, gastric cancer, liver cancer treatment drug. According to the centers for disease control and prevention of cancer epidemiology data released in recent years, the drug reimbursement to benefit patient population at least millions in a year, according to their family to calculate can benefit.
From China, of course, each year about 3.5 million the number of new onset of the tumor and cancer spectrum, these drugs are not enough. Such as high, compaq heap for domestic path, imported by bead sheet resistance, rituxan and drug lenalidomide has not been included. But the country has been supporting measures for some provinces and cities, which had to advance health care of a serious illness, and then will negotiate out 45 drugs into the medical insurance directory. Industry speculation, that 45 drug at least half of the tumor.
On the medical insurance directory still inherits the version of the rules, medical insurance directory of provinces and cities, and a 15% chance of regulation, some wealthy coastal provinces and cities have put local health insurance directory will be included in some curative effect affirmation, local demand for larger tumor drugs. Related enterprise must have the preparation, the drug into the health care just get an access to the growth of marketing, the price is still access the major threshold.
2009 medicare catalog once gave rise to a number of "excuse me medical insurance dividend" generate $1 billion in sales the myth of the future may be no more, unless it is accepted curative effect is extremely good "god". Related businesses need to be able to answer: "where is my medicine 'god'? How many patients can use?" Clinical dosage, prices have come down.
The author noted that the new medical insurance directory there is a small detail, namely of serial number and IMS health care drugs and drug serial number are identical, that the country in the directory update, in addition to considering the clinical curative effect, but also have good clinical dose data testing or research basis.
Express drug market
Announced on February 23, the new medical insurance directory, immediate cause is the "spring" in the stock market of new drug sector into the medical insurance directory variety production enterprise stock turns red, which means that our country 1.5 trillion ~ 2 trillion yuan drug market pattern to be reconstructed.
In today's market economy, medical insurance directory is guide the enterprise research and development production of drugs in the market: the future health care will tilt to major disease medication, the update is there a discount for cancer drugs in the future a long period, but the premise is the research and development production has a clear positioning, on the basis of is how much, the market competition intensity, patients develop me - me - or too better product strategy must consider to be clear about in advance, but all strategies must be followed drug curative effect and price.
The new shortlisted for the cancer drug was not a column in the world's most authoritative NCCN guidelines (global distribution of tumor treatment guidelines), and the evidence of evidence-based medicine (ebm) position in guide very sure, also recommend drugs is a line.
Pass the medical demand expression
In general, the remark on the scope of application of drugs to the identity of the more specialized, more clear, less marked another, second-line drugs to distinguish, more clear instruction which period of the drug should be used in clinical diagnosis, such as his west marina for high risk MDS.
The medical insurance directory, paclitaxel into class a reimbursement, he lifted the dorsey use restrictions (formerly second-line drugs), correct the printing defects. At home and abroad in the guide, dorsey he already is a line of drug use. These updates are reflected the directory changes highly professional.
Liposome yew is still not a finalist, the reason is the price and foreign guide didn't enter a line. Although liposome yew has certain pharmacokinetic advantage, but more common yew, at present has not been able to take out the advantage of pharmacoeconomics data persuade experts. These are the experts on marketing and product post-marketing clinical research and development (late) research "expression".
We has gone into the era of the precise therapy, drug marketing must also follow the precision promotion. Cancer drugs to increase indications or included in the scope of reimbursement, you must have evidence of evidence-based medicine, the evidence-based clinical verification and drug economics basis and must come from the data.
Domestic enterprises to promote the medicines few clinical trials of new exploration indications of marketed medicines. Who all understand the importance of into medical insurance directory, but often means is to look for experts, relations, public relations. This in the future will be more and more work, the medical insurance directory of the review process confidential almost unknown.
Medicare catalog is an important point, drug marketing market access to the path of the key point is: the research and development - indications - listed - clinical revalidation - into guidelines - into clinical practice guidelines (or path) - into the medical insurance directory, break through the key point is the only path to the clinical curative effect and efficacy of economics. Although some tumor drug turnover has amounted to several hundred million, listed a few years, why long tapping medicare catalog defeat, fundamental reason is the lack of clinical evidence of evidence-based medicine, or drug economics data.
The author argued that health insurance directory new drugs for relatively conservative, the current domestic research and development of enterprises more me - better medicine, especially tumor targeted drugs research and development, this is, after all, a relatively low-risk development road. The present situation of the domestic enterprises ignore the post-marketing clinical research must change, want to take out data, accurate, with data to convince experts is into the guide, the last into the future king of medical insurance directory. |
